{"Content: ":"Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd. In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.[1] Later, KCONVAC started phase II trials with 1,000 participants in China.[2] In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.[3] In August 2021, KCONVAC started phase I trials with 84 participants in China.[4] In September, KCONVAC started phase II trials with 480 participants in China.[5] On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[6]  This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.","Title":"Minhai COVID-19 vaccine - Wikipedia","KeyID":"11119","URL":"https://en.wikipedia.org/wiki/Minhai_COVID-19_vaccine"}